3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Colorectal Neoplasms
38
Pancreatic Neoplasms
16
Colonic Neoplasms
12
Rectal Neoplasms
11
Stomach Neoplasms
9
Neoplasms
9
Neuroblastoma
8
Small Cell Lung Carcinoma
7
Rhabdomyosarcoma
7
Neoplasm Metastasis
7
Glioblastoma
7
Sarcoma, Ewing
6
Gastrointestinal Neoplasms
6
Central Nervous System Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Glioma
5
Sarcoma
4
Brain Neoplasms
4
Medulloblastoma
3
Intestinal Neoplasms
3
Gliosarcoma
3
Gastrointestinal Diseases
3
Esophageal Neoplasms
3
Digestive System Neoplasms
3
Digestive System Diseases
3
Astrocytoma
3
Advanced Solid Tumors
3
Recurrence
2
Rectal Diseases
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Interventions
pembrolizumab
74
Nivolumab
53
Ipilimumab
42
Cyclophosphamide
32
Interleukin-2
24
aldesleukin
23
Temozolomide
17
fludarabine
16
Biopsy
11
trametinib
10
fludarabine phosphate
10
dabrafenib
10
spartalizumab
8
Paclitaxel
8
Dacarbazine
8
sargramostim
7
cemiplimab
7
binimetinib
7
Cisplatin
7
Bevacizumab
7
poly ICLC
6
lenvatinib
6
epacadostat
6
Radiotherapy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
encorafenib
5
atezolizumab
5
Vemurafenib
5
Specimen Handling
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Melanoma
×
Irinotecan
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts